{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T03:48:24Z","timestamp":1782013704983,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007281","name":"National Drug and Alcohol Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.drugalcdep.2020.108360","type":"journal-article","created":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T01:27:52Z","timestamp":1602984472000},"page":"108360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Characteristics and circumstances of death related to buprenorphine toxicity in Australia"],"prefix":"10.1016","volume":"218","author":[{"given":"Shane","family":"Darke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Duflou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briony","family":"Larance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lappin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108360_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs buprenorphine in France","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"issue":"S1","key":"10.1016\/j.drugalcdep.2020.108360_bib0010","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1080\/10550490490440780","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0015","series-title":"National Opioid Pharmacotherapy Statistics Annual Data Collection 2019","author":"Australian Institute of Health and Welfare","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0020","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1111\/1556-4029.12621","article-title":"An unusual case of death probably triggered by the association of buprenorphine at therapeutic dose with ethanol and benzodiazepines and with very low norbuprenorphine level","volume":"60","author":"Bardy","year":"2015","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0025","series-title":"Disposition of Toxic Drugs and Chemicals in Man","article-title":"Biomedical publications, CA","author":"Baselt","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0035","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/pme.12773","article-title":"Pharmaceutical opioid use and dependence among people living with chronic pain:associations observed within the Pain and Opioids in Treatment (POINT) Cohort","volume":"16","author":"Campbell","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0040","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1360-0443.2007.01980.x","article-title":"Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims","volume":"102","author":"Darke","year":"2007","journal-title":"Addict"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40265-018-0953-z","article-title":"Treating chronic pain, an overview of clinical studies centered on the buprenorphine option","volume":"78","author":"Davis","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/14737167.5.5.583","article-title":"Buprenorphine, buprenorphine\/naloxone and methadone maintenance: a cost-effectiveness analysis","volume":"5","author":"Doran","year":"2005","journal-title":"Expert Rev. Pharmacoeconomics Outcomes Res."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2017.01.016","article-title":"Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial","volume":"174","author":"Dunlop","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1520\/JFS14667J","article-title":"Fatal intoxication following self-administration of a massive dose of buprenorphine","volume":"45","author":"Gaulier","year":"2000","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00228-011-1122-4","article-title":"Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning","volume":"68","author":"H\u00e4kkinen","year":"2012","journal-title":"Euro. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.forsciint.2013.06.017","article-title":"Parenteral buprenorphine\u2013naloxone abuse is a major cause of fatal buprenorphine-related poisoning","volume":"232","author":"H\u00e4kkinen","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0075","series-title":"SPSS for Windows, 25.0","author":"IBM inc","year":"2017"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.12937","article-title":"Twenty\u2010five years of prescription opioid use in Australia, a whole\u2010of\u2010population analysis using pharmaceutical claims","volume":"82","author":"Karanges","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0085","series-title":"Karch\u2019s Pathology of Drug Abuse","author":"Karch","year":"2015"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0090","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0379-0738(01)00454-6","article-title":"Deaths involving buprenorphine, a compendium of French cases","volume":"121","author":"Kintz","year":"2001","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0095","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0009-9120(02)00304-1","article-title":"A new series of 13 buprenorphine-related deaths","volume":"35","author":"Kintz","year":"2002","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0025-6196(12)64946-5","article-title":"Age-related changes in normal human hearts during the first 10 decades of life. Part II (maturity), a quantitative anatomic study of 765 specimens from subjects 20 to 99 years old","volume":"63","author":"Kitzman","year":"1998","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.forsciint.2018.08.010","article-title":"High buprenorphine-related mortality is persistent in Finland","volume":"291","author":"Kriikku","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0110","first-page":"246","article-title":"2000 CDC growth charts for the United States: methods and development","volume":"11","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Statistics"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.forsciint.2006.03.037","article-title":"A survey of buprenorphine related deaths in Singapore","volume":"162","author":"Lai","year":"2006","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/dar.12277","article-title":"The introduction of buprenorphine\u2010naloxone film in opioid substitution therapy in Australia: uptake and issues arising from changing buprenorphine formulations","volume":"34","author":"Larance","year":"2015","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/dar.12344","article-title":"Diversion and injection of buprenorphine\u2013naloxone film two years post\u2010introduction in Australia","volume":"35","author":"Larance","year":"2016","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jemermed.2012.11.104","article-title":"Medical outcomes associated with nonmedical use of methadone and buprenorphine","volume":"45","author":"Lee","year":"2013","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugalcdep.2014.02.014","article-title":"Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone","volume":"138","author":"Lee","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0140","series-title":"Poisoning and Toxicology Handbook","author":"Leikin","year":"2015"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2012.12.009","article-title":"A randomised controlled trial of sublingual buprenorphine\u2013naloxone film versus tablets in the management of opioid dependence","volume":"131","author":"Lintzeris","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0150","series-title":"Clinical Guidelines for Use of Depot Buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the Treatment of Opioid Dependence","author":"Lintzeris","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse, the current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0160","article-title":"A systematic review of the effectiveness of buprenorphine for opioid use disorder compared to other treatments, implications for research and practice","volume":"10","author":"Mariolis","year":"2019","journal-title":"J. Addict. Res. Ther."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007629","article-title":"The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales","volume":"5","author":"Marteau","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0170","first-page":"2","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drugalcdep.2009.12.008","article-title":"A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification, a mixed treatment comparison meta-analysis","volume":"108","author":"Meader","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1360-0443.2001.96226710.x","article-title":"Injecting misuse of buprenorphine among French drug users","volume":"96","author":"Obadia","year":"2001","journal-title":"Addict"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pcad.2018.06.004","article-title":"Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update","volume":"61","author":"Pich\u00e9","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0190","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1360-0443.2004.00790.x","article-title":"A critical review of the causes of death among post-mortem toxicological investigations, analysis of 34 buprenorphine-associated and 35 methadone-associated deaths","volume":"99","author":"Pirnay","year":"2004","journal-title":"Addict."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1742-7843.2008.00273.x","article-title":"Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats","volume":"103","author":"Pirnay","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0200","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1046\/j.1360-0443.1998.93913859.x","article-title":"Six deaths linked to concomitant use of buprenorphine and benzodiazepines","volume":"93","author":"Reynaud","year":"1998","journal-title":"Addict"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/hup.698","article-title":"Buprenorphine mortality, seizures and prescription data in the UK, 1980\u20132002","volume":"20","author":"Schifano","year":"2005","journal-title":"Human Pychopharmacol Clin. Exp."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0210","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0025-6196(12)64945-3","article-title":"Age-related changes in normal human hearts during the first 10 decades of life. Part I (growth), a quantitative anatomic study of 200 specimens from subjects from birth to 19 years old","volume":"63","author":"Scholz","year":"1998","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0215","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.forsciint.2012.03.016","article-title":"Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome","volume":"220","author":"Seld\u00e9n","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0220","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence, a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France, a report on 20 fatalities","volume":"22","author":"Tracqui","year":"1998","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0230","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder, a randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0235","first-page":"29","article-title":"Buprenorphine, a (relatively) new treatment for opioid dependence","volume":"2","author":"Welsh","year":"2005","journal-title":"Psychiatry Edgmont (Edgmont)"},{"key":"10.1016\/j.drugalcdep.2020.108360_bib0240","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dar.12143","article-title":"Opioid\u2010related mortality and filled prescriptions for buprenorphine and methadone","volume":"33","author":"Wikner","year":"2014","journal-title":"Drug Alcohol Rev."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620305251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620305251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:09:52Z","timestamp":1759828192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620305251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":48,"alternative-id":["S0376871620305251"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108360","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and circumstances of death related to buprenorphine toxicity in Australia","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108360"}}